Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Conditions
Berger Disease · Bergers Disease · IgA Nephropathy · Immunoglobulin A Nephropathy · Primary IgAN · Nephritis IgA Type, Nephropathy IgA Type
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hackensack Meridian Health, Neptune City, New Jersey, United States
Cincinnati Childrens Hospital MC, Cincinnati, Ohio, United States
University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
University of Tennessee Health Science Center- Le Bonheur Research Center, Memphis, Tennessee, United States
Novartis Investigative Site, Nagoya, Aichi-ken, Japan
Novartis Investigative Site, Fukuoka, Japan
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals